Behavioral stress accelerates prostate cancer development in mice.

Prostate cancer patients have increased levels of stress and anxiety. Conversely, men who take beta blockers, which interfere with signaling from the stress hormones adrenaline and noradrenaline, have a lower incidence of prostate cancer; however, the mechanisms underlying stress-prostate cancer interactions are unknown. Here, we report that stress promotes prostate carcinogenesis in mice in an adrenaline-dependent manner. Behavioral stress inhibited apoptosis and delayed prostate tumor involution both in phosphatase and tensin homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in prostate tumors of mice with prostate-restricted expression of c-MYC (Hi-Myc mice) subjected to androgen ablation therapy with bicalutamide. Additionally, stress accelerated prostate cancer development in Hi-Myc mice. The effects of stress were prevented by treatment with the selective β2-adrenergic receptor (ADRB2) antagonist ICI118,551 or by inducible expression of PKA inhibitor (PKI) or of BCL2-associated death promoter (BAD) with a mutated PKA phosphorylation site (BADS112A) in xenograft tumors. Effects of stress were also blocked in Hi-Myc mice expressing phosphorylation-deficient BAD (BAD3SA). These results demonstrate interactions between prostate tumors and the psychosocial environment mediated by activation of an adrenaline/ADRB2/PKA/BAD antiapoptotic signaling pathway. Our findings could be used to identify prostate cancer patients who could benefit from stress reduction or from pharmacological inhibition of stress-induced signaling.

[1]  Morten Wang Fagerland,et al.  Use of β‐blockers is associated with prostate cancer‐specific survival in prostate cancer patients on androgen deprivation therapy , 2013, The Prostate.

[2]  F. Salsbury,et al.  Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug. , 2012, Journal of medicinal chemistry.

[3]  A. Levine,et al.  Chronic restraint stress attenuates p53 function and promotes tumorigenesis , 2012, Proceedings of the National Academy of Sciences.

[4]  Steven W. Cole,et al.  Molecular Pathways: Beta-Adrenergic Signaling in Cancer , 2011, Clinical Cancer Research.

[5]  Kunhong Xiao,et al.  A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1 , 2011, Nature.

[6]  A. Sood,et al.  The sympathetic nervous system induces a metastatic switch in primary breast cancer. , 2010, Cancer research.

[7]  A. Sood,et al.  Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis* , 2010, The Journal of Biological Chemistry.

[8]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[9]  M. During,et al.  Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Leptin Axis Causes Cancer Remission and Inhibition , 2010, Cell.

[10]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[11]  Liz Y. Han,et al.  Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. , 2010, The Journal of clinical investigation.

[12]  Steve W. Cole,et al.  Neuroendocrine modulation of cancer progression , 2009, Brain, Behavior, and Immunity.

[13]  N. Danial.  BAD: undertaker by night, candyman by day , 2008, Oncogene.

[14]  B. Hoffman,et al.  Apoptotic signaling by c-MYC , 2008, Oncogene.

[15]  P. Carroll,et al.  Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention , 2008, Proceedings of the National Academy of Sciences.

[16]  A. Sood,et al.  Neuroendocrine influences on cancer biology. , 2008, Seminars in cancer biology.

[17]  S. Dhanasekaran,et al.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. , 2007, Cancer cell.

[18]  G. Page,et al.  Named Series: Twenty years of Brain, Behavior, and Immunity Stress, NK cells, and cancer: Still a promissory note , 2007 .

[19]  N. Barnard,et al.  Diet and survival after prostate cancer diagnosis. , 2007, Nutrition reviews.

[20]  George Kulik,et al.  Epinephrine Protects Cancer Cells from Apoptosis via Activation of cAMP-dependent Protein Kinase and BAD Phosphorylation* , 2007, Journal of Biological Chemistry.

[21]  Ximing J. Yang,et al.  Tumor suppressor activity of glucocorticoid receptor in the prostate , 2007, Oncogene.

[22]  P. Lichter,et al.  Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays , 2006, British Journal of Cancer.

[23]  T. Downs,et al.  Potential Attenuation of Disease Progression in Recurrent Prostate Cancer With Plant-Based Diet and Stress Reduction , 2006, Integrative cancer therapies.

[24]  Sandeep Robert Datta,et al.  Diverse Antiapoptotic Signaling Pathways Activated by Vasoactive Intestinal Polypeptide, Epidermal Growth Factor, and Phosphatidylinositol 3-Kinase in Prostate Cancer Cells Converge on BAD* , 2006, Journal of Biological Chemistry.

[25]  Liz Y. Han,et al.  Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma , 2006, Nature Medicine.

[26]  F. Montorsi,et al.  Pathological changes of high‐grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg , 2006, BJU international.

[27]  T. L. Drell,et al.  The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers , 2006, International journal of cancer.

[28]  R. Panettieri,et al.  Cytokines regulate beta-2-adrenergic receptor responsiveness in airway smooth muscle via multiple PKA- and EP2 receptor-dependent mechanisms. , 2005, Biochemistry.

[29]  Neal Rosen,et al.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. , 2005, Cancer cell.

[30]  P. Casey,et al.  Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.

[31]  M. McClintock,et al.  Chronic stress accelerates ultraviolet-induced cutaneous carcinogenesis. , 2004, Journal of the American Academy of Dermatology.

[32]  I. Bairati,et al.  Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada) , 2004, Cancer Causes & Control.

[33]  Mahadev Rao,et al.  The Androgen Receptor Acetylation Site Regulates cAMP and AKT but Not ERK-induced Activity* , 2004, Journal of Biological Chemistry.

[34]  M. Massie.  Prevalence of depression in patients with cancer. , 2004, Journal of the National Cancer Institute. Monographs.

[35]  M. Gleave,et al.  Androgens and prostate cancer , 2003, World Journal of Urology.

[36]  A. Vitiello,et al.  Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[38]  David Spiegel,et al.  Depression and cancer: mechanisms and disease progression , 2003, Biological Psychiatry.

[39]  R. Babaian,et al.  Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[40]  D. Pasco,et al.  Evaluation of β-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP , 2003 .

[41]  S. Lutgendorf,et al.  Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. , 2003, The Journal of urology.

[42]  S. R. Datta,et al.  Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. , 2002, Developmental cell.

[43]  F. Bethencourt,et al.  Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. , 2002, European cytokine network.

[44]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[45]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[46]  M. Pollak,et al.  Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. , 1999, Urology.

[47]  E. Mezzacappa,et al.  Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. , 1999, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[48]  Susan S. Taylor,et al.  Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. , 1999, Molecular cell.

[49]  M. Sadar.  Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways* , 1999, The Journal of Biological Chemistry.

[50]  A. Brinkmann,et al.  Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. , 1998, Biochemistry.

[51]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[52]  A. Klippel,et al.  Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.

[53]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[54]  R. Lefkowitz,et al.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.

[55]  N. Kyprianou,et al.  Androgen regulation of programmed death of normal and malignant prostatic cells. , 1992, Journal of andrology.

[56]  F. Braceland.  THE STRESS OF LIFE , 1976 .

[57]  K. Krobert,et al.  Hormonal regulation of β2‐adrenergic receptor level in prostate cancer , 2008, The Prostate.

[58]  D. Pasco,et al.  Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. , 2003, Biochemical pharmacology.

[59]  A. Shaywitz,et al.  CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. , 1999, Annual review of biochemistry.

[60]  A. Gousse,et al.  Beta adrenergic receptor alterations in diabetic rat prostate: Effects of insulin and dietary myoinositol , 1991, The Prostate.

[61]  A. Goldstein,et al.  Stress prostatitis. , 1989, Urology.

[62]  P. Poyet,et al.  Characteristics of the β‐adrenergic stimulation of adenylate cyclase activity in rat ventral prostate and its modulation by androgens , 1986, The Prostate.

[63]  R. Dulbecco.  Genes in cancer. , 1983, Folia biologica.